CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Lu et al. [111] showed that treatment with TKI reduces the percentage of T, Treg, CD4+, and CD8+ T cells to a different extent depending on the TKI used in CML patients compared to healthy controls.